X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4943) 4943
Publication (378) 378
Book Review (37) 37
Newsletter (16) 16
Book Chapter (8) 8
Conference Proceeding (7) 7
Magazine Article (6) 6
Newspaper Article (5) 5
Dissertation (2) 2
Presentation (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4504) 4504
capecitabine (4084) 4084
female (3259) 3259
oncology (3179) 3179
index medicus (2836) 2836
antineoplastic combined chemotherapy protocols - therapeutic use (2733) 2733
deoxycytidine - analogs & derivatives (2695) 2695
middle aged (2622) 2622
aged (2500) 2500
fluorouracil - analogs & derivatives (2394) 2394
male (2194) 2194
chemotherapy (2112) 2112
adult (2024) 2024
deoxycytidine - administration & dosage (1813) 1813
fluorouracil - administration & dosage (1744) 1744
treatment outcome (1585) 1585
cancer (1509) 1509
breast neoplasms - drug therapy (1145) 1145
deoxycytidine - therapeutic use (1098) 1098
antineoplastic combined chemotherapy protocols - adverse effects (1027) 1027
fluorouracil - therapeutic use (955) 955
fluorouracil (872) 872
aged, 80 and over (870) 870
oxaliplatin (857) 857
colorectal neoplasms - drug therapy (855) 855
care and treatment (853) 853
disease-free survival (820) 820
deoxycytidine - adverse effects (816) 816
antimetabolites, antineoplastic - therapeutic use (805) 805
therapy (805) 805
breast cancer (795) 795
5-fluorouracil (785) 785
metastasis (776) 776
organoplatinum compounds - administration & dosage (775) 775
colorectal cancer (772) 772
neoplasm staging (758) 758
antineoplastic agents - therapeutic use (752) 752
breast neoplasms - pathology (738) 738
neoplasm metastasis (729) 729
fluorouracil - adverse effects (717) 717
pharmacology & pharmacy (684) 684
survival (620) 620
bevacizumab (608) 608
trial (605) 605
research (590) 590
medicine & public health (588) 588
retrospective studies (562) 562
survival rate (555) 555
prognosis (554) 554
adenocarcinoma - drug therapy (525) 525
combination (524) 524
colorectal neoplasms - pathology (500) 500
stomach neoplasms - drug therapy (496) 496
carcinoma (491) 491
1st-line treatment (488) 488
drug administration schedule (488) 488
hematology, oncology and palliative medicine (487) 487
drug therapy (471) 471
survival analysis (467) 467
chemotherapy, adjuvant (461) 461
leucovorin (452) 452
camptothecin - analogs & derivatives (448) 448
surgery (441) 441
clinical trials (436) 436
irinotecan (422) 422
cisplatin (420) 420
docetaxel (417) 417
radiotherapy (411) 411
gemcitabine (408) 408
antineoplastic combined chemotherapy protocols - administration & dosage (405) 405
phase-ii (404) 404
trastuzumab (404) 404
antimetabolites, antineoplastic - adverse effects (396) 396
antineoplastic agents (395) 395
capecitabine - administration & dosage (392) 392
analysis (382) 382
cancer research (381) 381
administration, oral (379) 379
phase-ii trial (379) 379
follow-up studies (377) 377
antimitotic agents (369) 369
tumors (362) 362
combined modality therapy (361) 361
antimetabolites, antineoplastic - administration & dosage (357) 357
camptothecin - administration & dosage (357) 357
leucovorin - administration & dosage (357) 357
paclitaxel (355) 355
disease progression (352) 352
taxoids - administration & dosage (344) 344
phase-iii trial (342) 342
neoadjuvant therapy (340) 340
health aspects (339) 339
stomach neoplasms - pathology (336) 336
cancer therapies (332) 332
adenocarcinoma (327) 327
oral capecitabine (323) 323
cisplatin - administration & dosage (319) 319
kaplan-meier estimate (319) 319
prospective studies (308) 308
metastatic colorectal-cancer (306) 306
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4632) 4632
Japanese (157) 157
Chinese (52) 52
French (36) 36
German (29) 29
Italian (13) 13
Russian (13) 13
Spanish (12) 12
Dutch (8) 8
Hungarian (6) 6
Czech (4) 4
Korean (3) 3
Polish (3) 3
Romanian (2) 2
Danish (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Portuguese (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1355 - 1369
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 07/2014, Volume 12, Issue 7, pp. 1028 - 1059
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance,... 
PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | UNRESECTABLE LIVER METASTASES | BEVACIZUMAB-CONTAINING ARMS | ONCOLOGY | HIGH-DOSE LEUCOVORIN | POSTPROGRESSION SURVIVAL-TIME | 1ST-LINE COMBINATION CHEMOTHERAPY | KRAS WILD-TYPE | CAPECITABINE PLUS OXALIPLATIN | METASTATIC COLORECTAL-CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Bevacizumab | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Deoxycytidine - adverse effects | Leucovorin - therapeutic use | Cetuximab | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Membrane Proteins - genetics | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1007 - 1018
Summary Background Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human,... 
Hematology, Oncology and Palliative Medicine | AMPLIFICATION | PHARMACOKINETICS | ONCOLOGY | HEPATOCYTE GROWTH-FACTOR | C-MET | MONOCLONAL-ANTIBODY | CIRCULATING LEVEL | AMG 102 | CANCER | EXPRESSION | CARCINOMA | Confidence Intervals | Adenocarcinoma - pathology | Esophagogastric Junction - drug effects | Prognosis | Capecitabine | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Stomach Neoplasms - pathology | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Neoplasm Invasiveness - pathology | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Proportional Hazards Models | Esophagogastric Junction - pathology | Survival Rate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Epirubicin - therapeutic use | Aged | Neoplasm Staging | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Epirubicin - adverse effects | Monoclonal antibodies | Anthracyclines | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 26, pp. 2733 - 2743
Journal Article
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy... 
SURGERY | REGRESSION | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESECTION | CHEMORADIOTHERAPY | OPEN-LABEL | ESOPHAGEAL | CANCER | STOMACH | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Metastases | Confidence intervals | Infusion | Oxaliplatin | Motivation | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 19, pp. 1783 - 1791
Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to... 
CAPECITABINE | LAPATINIB | MEDICINE, GENERAL & INTERNAL | THERAPY | PHASE-II | ANTIBODY | RECEPTOR | PLUS | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Trastuzumab | Drugs | Dose-response relationship (Biochemistry) | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Comparative analysis | Thrombocytopenia | Chemotherapy | Epidermal growth factor | Vomiting | Diarrhea | Cytotoxicity | Nausea | Survival | ErbB-2 protein | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 149 - 156
Journal Article